Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of CM336 monotherapy versus investigator's choice standard of care in relapsed or refractory multiple myeloma after at least 2 prior lines
CTR20253718Phase 3Active
- Sponsor
- Keymed Biosciences
- Start
- Oct 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of gamgertamig in multiple myeloma (MM), sponsored by Keymed Biosciences. Started Oct 2025; status: active.
02
Drugs
gamgertamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20253718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253718.